A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

Nature Genetics

Volumn 47, Issue 9, 2015, Pages 1079-1084

  Aminkeng, Folefac ^a,b   Bhavsar, Amit P ^a,b   Visscher, Henk ^a,c   Rassekh, Shahrad R ^a,b   Li, Yuling ^a,b   Lee, Jong W ^a,b   Brunham, Liam R ^d   Caron, Huib N ^e   Van Dalen, Elvira C ^e   Kremer, Leontien C ^e   Van Der Pal, Helena J ^e   Amstutz, Ursula ^a,b,i   Rieder, Michael J ^f   Bernstein, Daniel ^g   Carleton, Bruce C ^a,b,h   Hayden, Michael R ^a,b,d   Ross, Colin J D ^a,b,h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e EMMA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g STANFORD UNIVERSITY   (United States)

^h BC CHILDREN S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; RETINOIC ACID RECEPTOR GAMMA; ANTINEOPLASTIC ANTIBIOTIC; RETINOIC ACID RECEPTOR;

ADULT; ANTHRACYCLINE INDUCED CARDIOTOXICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MEGADOSE; EUROPEAN; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE REPLICATION; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART LEFT VENTRICLE FAILURE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; BONE NEOPLASMS; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; HEART LEFT VENTRICLE FUNCTION; PRESCHOOL CHILD; RHABDOMYOSARCOMA; SARCOMA, EWING; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, RETINOIC ACID; RHABDOMYOSARCOMA; SARCOMA, EWING; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84940605296     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3374     Document Type: Article

References (59)

1. Smith, L.A. et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10, 337 (2010).
2. van der Pal, H.J. et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch. Intern. Med. 170, 1247-1255 (2010).
3. van der Pal, H.J. et al. High risk of symptomatic cardiac events in childhood cancer survivors. J. Clin. Oncol. 30, 1429-1437 (2012).
4. Armenian, S.H. et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br. J. Haematol. 163, 205-213 (2013).
5. Blanco, J.G. et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112, 2789-2795 (2008).
6. Blanco, J.G. et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J. Clin. Oncol. 30, 1415-1421 (2012).
7. Lipshultz, S.E. et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 119, 3555-3562 (2013).
8. Lubieniecka, J.M. et al. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Front. Genet. 4, 231 (2013).
9. Rajić, V. et al. Infuence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk. Lymphoma 50, 1693-1698 (2009).
10. Rossi, D. et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23, 1118-1126 (2009).
11. Semsei, A.F. et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol. Int. 36, 79-86 (2012).
12. Visscher, H. et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. 30, 1422-1428 (2012).
13. Visscher, H. et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer 60, 1375-1381 (2013).
14. Wang, X. et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the Children's Oncology Group. J. Clin. Oncol. 32, 647-653 (2014).
15. Windsor, R.E., Strauss, S.J., Kallis, C., Wood, N.E. & Whelan, J.S. Germline genetic polymorphisms may infuence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 118, 1856-1867 (2012).
16. Wojnowski, L. et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112, 3754-3762 (2005).
17. Volkan-Salanci, B. et al. The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms. J. Chemother. 24, 285-291 (2012).
18. Lubieniecka, J.M. et al. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy. Cancer Epidemiol. Biomarkers Prev. 21, 2118-2120 (2012).
19. Cascales, A. et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist 18, 446-453 (2013).
20. Cascales, A. et al. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int. J. Cardiol. 154, 282-286 (2012).
21. Vivenza, D. et al. Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int. J. Biol. Markers 28, e336-e347 (2013).
22. Sachidanandam, K., Gayle, A.A., Robins, H.I. & Kolesar, J.M. Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine N-methyl transferase. J. Oncol. Pharm. Pract. 19, 269-272 (2013).
23. Krischer, J.P. et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol. 15, 1544-1552 (1997).
24. Hasan, S., Dinh, K., Lombardo, F. & Kark, J. Doxorubicin cardiotoxicity in African Americans. J. Natl. Med. Assoc. 96, 196-199 (2004).
25. Hershman, D. et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J. Clin. Oncol. 23, 6639-6646 (2005).
26. Duan, S. et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67, 5425-5433 (2007).
27. Peters, E.J. et al. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 12, 1407-1415 (2011).
28. Lipshultz, S.E., Alvarez, J.A. & Scully, R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94, 525-533 (2008).
29. Barry, E., Alvarez, J.A., Scully, R.E., Miller, T.L. & Lipshultz, S.E. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother. 8, 1039-1058 (2007).
30. Agarwala, S. et al. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J. Pediatr. Surg. 35, 1786-1789 (2000).
31. Shaikh, A.S., Saleem, A.F., Mohsin, S.S., Alam, M.M. & Ahmed, M.A. Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open 3, e003663 (2013).
32. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954 (1996).
33. Tang, Q. et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res. 71, 6940-6947 (2011).
34. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229 (2004).
35. Zhang, S. et al. Identifcation of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
36. Lyu, Y.L. et al. Topoisomerase IIβ mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 67, 8839-8846 (2007).
37. Bilbija, D. et al. Retinoic acid signalling is activated in the postischemic heart and may infuence remodelling. PLoS ONE 7, e44740 (2012).
38. Delacroix, L. et al. Cell-specifc interaction of retinoic acid receptors with target genes in mouse embryonic fbroblasts and embryonic stem cells. Mol. Cell. Biol. 30, 231-244 (2010).
39. Wheeler, H.E., Maitland, M.L., Dolan, M.E., Cox, N.J. & Ratain, M.J. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 14, 23-34 (2013).
40. McLeod, H.L. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 339, 1563-1566 (2013).
41. Nelson, M.R. et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 9, 23-33 (2009).
42. Ortega, J.J. et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J. Clin. Oncol. 23, 7632-7640 (2005).
43. Pellicori, P., Calicchia, A., Lococo, F., Cimino, G. & Torromeo, C. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol. Congest. Heart Fail. 18, 217-221 (2012).
44. Arima, K. et al. Global analysis of RAR-responsive genes in the Xenopus neurula using cDNA microarrays. Dev. Dyn. 232, 414-431 (2005).
45. Palm-Leis, A. et al. Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-trans retinoic acid on the hypertrophic growth of cardiomyocytes. J. Biol. Chem. 279, 54905-54917 (2004).
46. Simandi, Z., Balint, B.L., Poliska, S., Ruhl, R. & Nagy, L. Activation of retinoic acid receptor signaling coordinates lineage commitment of spontaneously differentiating mouse embryonic stem cells in embryoid bodies. FEBS Lett. 584, 3123-3130 (2010).
47. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
48. Rodvold, K.A., Rushing, D.A. & Tewksbury, D.A. Doxorubicin clearance in the obese. J. Clin. Oncol. 6, 1321-1327 (1988).
49. Kremer, L.C., van Dalen, E.C., Offringa, M., Ottenkamp, J. & Voute, P.A. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol. 19, 191-196 (2001).
50. Lipshultz, S.E. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324, 808-815 (1991).
51. Lipshultz, S.E. et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. 332, 1738-1743 (1995).
52. Altman, A.J. in Supportive Care of Children with Cancer: Current Therapy and Guidelines from the Children's Oncology Group 3rd edn. (ed. Lacuone, J.) 139-148 (John Hopkins University Press, 2004).
53. Mulrooney, D.A. et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. Br. Med. J. 339, b4606 (2009).
54. Visscher, H. et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics (in the press).
55. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
56. Pruim, R.J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336-2337 (2010).
57. Browning, S.R. & Browning, B.L. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am. J. Hum. Genet. 81, 1084-1097 (2007).
58. Visscher, H. et al. Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics J. 9, 362-372 (2009).
59. Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997-1004 (1999).